David Smith is the Vice President at BioCentriq, leading the Manufacturing, Science, and Technology (MS&T), Process Development, and Analytical Method Development teams. With over 15 years in regenerative medicine, he has significant experience in advancing cell therapy manufacturing. David has previously held key roles at Ori Biotech and Minaris Regenerative Medicine, focusing on process optimization and quality assurance. His expertise includes experimental design and quality-by-design, contributing to advancements in CAR-T cell production. David is committed to driving innovation and ensuring compliance with industry standards for efficient, scalable manufacturing.

The district bonds may be made registerable as to principal alone or as to both principal and interest under such terms and conditions as may be fixed by the board prior to the issuance thereof.

CAR-T cell therapy represents a significant advancement in regenerative medicine, but the journey to commercialization is complex. This comprehensive study conducted in partnership with Terumo Blood and Cell Technologies, highlighted key factors necessary for a successful manufacturing process.

In June, BioCentriq hosted a webinar called End-to-End Automated Manufacturing of Low-Seed CAR-T Cells where we explored the intricate pathway to achieving commercial readiness in CAR-T cell therapy. In this session, we address crucial aspects such as scalability, process development, cost management, and GMP compliance.